DALLAS - Spectral AI, Inc. (NASDAQ:MDAI), an AI company specializing in medical diagnostics for wound care, announced the appointment of Dr. J. Michael DiMaio to its Board of Directors as a non-executive member. The appointment, effective as of last Tuesday, fills a vacancy following the departure of Mr. Michael Murphy. Dr. DiMaio, a co-founder and former CEO and Chairman of Spectral AI, is a renowned surgeon and an influential figure in the medical community.
Dr. DiMaio's return to the board is seen as a strategic move as Spectral AI prepares for the commercialization of its DeepView® System, a diagnostic device aimed at improving wound care management. His extensive experience in patient care, medical device technologies, and leadership in cardiovascular programs is expected to be invaluable for the company's growth and product development.
In addition to the board appointment, Spectral AI disclosed that Dr. DiMaio and Erich Spangenberg, who collectively hold about 45% of the company's outstanding shares, have agreed to extend their lock-up agreements for an additional 180 days. This extension follows their previous agreement in September 2023, indicating a continued commitment to the company's long-term prospects.
Spectral AI's DeepView® System is designed to provide clinicians with an objective assessment of a wound's healing potential, which could lead to improved patient outcomes and reduced healthcare costs. The company's focus is on addressing unmet clinical needs in wound care, with initial applications for patients with burns and diabetic foot ulcers.
The information in this article is based on a press release statement from Spectral AI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.